慢性假体周围感染中仅少数患者符合单阶段翻修指征
本研究回顾性分析120例慢性假体周围感染(PJI)患者,其中108例可评估,仅19%(20/108)符合国际共识会议单阶段翻修指征。在符合指征并接受两阶段翻修的患者中,2年感染持续或复发比例与不符合指征者无差异(3/15 vs 32% [24/76],p=0.38)。结论认为单阶段翻修适用人群比例小,两阶段翻修后感染风险差异需更大样本研究验证。
要点
- 慢性PJI患者中仅19%符合单阶段翻修的国际共识指征。
- 符合指征者接受两阶段翻修后2年感染复发率与不符合者无显著差异。
- 单阶段翻修在慢性PJI中应用极少(3%),仅用于肿瘤假体患者。
核心结论
- 仅小部分慢性PJI患者适合单阶段直接翻修。
- 符合单阶段指征者接受两阶段翻修后感染风险与不符合者无差异,但样本量小需谨慎解读。
研究设计与样本
- 回顾性研究,单中心2012-2016年治疗120例慢性PJI患者,最终91例纳入分析。
- 单阶段翻修仅用于3%(4/120)肿瘤假体患者,7%(8/120)接受其他手术,16%(17/108)失访。
主要发现
- 108例中仅19%(20/108)符合国际共识会议单阶段翻修指征。
- 符合与不符合指征者2年感染持续或复发比例分别为3/15和32%(24/76),p=0.38。
关键数值与推荐
- 单阶段翻修指征:术前已知非毒力病原体、宿主免疫正常、软组织包膜健康无窦道。
- 感染判断采用肌肉骨骼感染学会(MSIS)标准。
临床怎么用
- 临床中应严格评估慢性PJI患者是否符合单阶段翻修指征,多数患者可能更适合两阶段翻修。
- 符合单阶段指征者若行两阶段翻修,感染风险未必更低,需个体化决策。
局限性
- 回顾性设计,样本量小(91例),可能遗漏重要差异。
- 单阶段翻修仅用于肿瘤假体患者,未直接比较单阶段与两阶段翻修。
- 16%患者失访,可能引入偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Periprosthetic joint infection (PJI) is a leading cause of revision arthroplasty. Considerable controversy still exists whether single- or two-stage exchange is the better approach for patients with chronic PJI. Historically, single-stage exchange arthroplasty was thought to have an unacceptably high risk of reinfection compared with two-stage exchange but recent studies have demonstrated that this may not be the case. To be considered for single-stage exchange, patients should meet certain criteria including a preoperatively identified nonvirulent pathogen in an immunocompetent host with an uncompromised soft tissue envelope. It is unclear what proportion of patients with chronic PJI actually meet these criteria. Additionally, patients who meet the criteria for single-stage exchange are selected because, in principle, they may be more likely to be able to overcome the infection, but it is unknown what the reinfection risk is in patients undergoing two-stage exchange who might have met selection criteria for single-stage exchange. QUESTIONS/PURPOSES: (1) What percentage of patients with chronic PJI treated at our institution met the International Consensus Meeting criteria for single-stage exchange arthroplasty? (2) Is the risk of persistent or recurrent infection lower for patients treated with two-stage exchange who met International Consensus Meeting criteria for single-stage exchange than it is among those who did not meet those inclusion criteria? METHODS: Between 2012 and 2016, one referral center treated 120 patients with chronic PJI as determined by Musculoskeletal Infection Society (MSIS) criteria. During this time, we used single-stage exchange only rarely in patients with chronic PJI (3%; four of 120), and only in oncologic patients with mega-prosthesis implants; 7% (eight of 120) underwent other procedures (resection arthroplasty or arthrodesis). Of the remaining 108, 16% (17) were lost to follow-up; the remaining 91 were evaluated in this retrospective study. To answer our first question, we applied the International Consensus Meeting indications for single-stage exchange, which were a known nonvirulent preoperative organism, an immunocompetent host, and a healthy soft-tissue envelope without a sinus tract; we then calculated the percentage of patients who would have met those criteria. To answer our second question, we compared those who would and would not have met those criteria in terms of the proportion who were determined to be infection-free at 2 years using the MSIS criteria. RESULTS: Only 19% (20 of 108) of patients met the International Consensus Meeting criteria for single-stage exchange. With the numbers available, there was no difference between those who met and did not meet those criteria in terms of the proportion of patients who had persistent or recurrent infection 2 years after treatment (three of 15 versus 32% [24 of 76]; p = 0.38). CONCLUSIONS: We found that only a small proportion of patients who presented with chronic PJI to a referral center would have been suitable for single-stage direct exchange; with the numbers available, we found no difference in the reinfection risk after two-stage revision in those patients compared with those who would not have met those criteria. Consequently, it is possible that a small proportion of patients may benefit from single-stage exchange, but our small sample size may have missed important differences in reinfection risk, and so our findings on that question must be considered preliminary. Larger studies randomizing patients who meet single-stage criteria to either single- or two-stage exchange will better elucidate the true reinfection risk in this patient population. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Dombrowski ME, Wilson AE, Wawrose RA, et al. A Low Percentage of Patients Satisfy Typical Indications for Single-stage Exchange Arthroplasty for Chronic Periprosthetic Joint Infection. Clin Orthop Relat Res. 2020. PMID: 32281770. doi:10.1097/CORR.0000000000001243
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。